ValuEngine downgraded shares of Sophiris Bio (NASDAQ:SPHS) from a hold rating to a sell rating in a research report released on Tuesday morning, ValuEngine reports.

Other research analysts also recently issued research reports about the stock. Piper Jaffray Companies dropped their target price on shares of Sophiris Bio to $5.00 and set an overweight rating on the stock in a research note on Wednesday, March 13th. HC Wainwright dropped their target price on shares of Sophiris Bio from $10.00 to $3.50 and set a buy rating on the stock in a research note on Thursday, March 14th. Finally, Maxim Group reiterated a hold rating on shares of Castle Brands in a research note on Wednesday, June 19th.

Shares of SPHS opened at $1.05 on Tuesday. The business has a 50-day simple moving average of $0.83. The stock has a market capitalization of $30.22 million, a PE ratio of -2.02 and a beta of 2.80. Sophiris Bio has a fifty-two week low of $0.71 and a fifty-two week high of $3.49. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 2.93.

Sophiris Bio (NASDAQ:SPHS) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. On average, sell-side analysts forecast that Sophiris Bio will post -0.36 EPS for the current fiscal year.

An institutional investor recently raised its position in Sophiris Bio stock. Geode Capital Management LLC grew its holdings in Sophiris Bio Inc (NASDAQ:SPHS) by 14.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 243,523 shares of the biopharmaceutical company’s stock after acquiring an additional 31,579 shares during the period. Geode Capital Management LLC owned 0.81% of Sophiris Bio worth $202,000 as of its most recent SEC filing. 8.27% of the stock is currently owned by institutional investors and hedge funds.

Sophiris Bio Company Profile

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Recommended Story: Do back-end load funds outperform no-load funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with's FREE daily email newsletter.